Valuation Alnylam Pharmaceuticals, Inc.

Stocks

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-10 pm EDT			5-day change	1st Jan Change
291.22 ^USD	-2.17%		-0.46%	-26.76%

08:10am	Alnylam, Genesis Pharma Expand Commercial Partnership Into 4 Nordic Markets	MT
Jun. 09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11:20 AM

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	20,282	29,238	24,021	30,350	52,535	39,745	-	-
Change	-	44.16%	-17.84%	26.35%	73.09%	-24.35%	-	-
Enterprise Value (EV) ¹	18,522	28,132	23,979	30,128	52,325	36,809	34,843	32,659
Change	-	51.88%	-14.76%	25.64%	73.67%	-29.65%	-5.34%	-6.27%
P/E ratio	-23.6x	-25.6x	-54.4x	-108x	171x	38.9x	27.1x	20.9x
PBR	34.6x	-186x	-109x	453x	66.7x	18.7x	9.7x	6.16x
PEG	-	-0.9x	0.9x	2.8x	-1x	0x	0.6x	0.7x
Capitalization / Revenue	24x	28.2x	13.1x	13.5x	14.1x	7.08x	5.44x	4.56x
EV / Revenue	21.9x	27.1x	13.1x	13.4x	14.1x	6.56x	4.77x	3.75x
EV / EBITDA	-28x	-38x	-105x	-251x	93.9x	28.4x	19.3x	14.6x
EV / EBIT	-26.1x	-35.8x	-85x	-170x	104x	28.5x	18.9x	13.6x
EV / FCF	-25.8x	-45.9x	572x	-707x	112x	27.6x	18.1x	13.5x
FCF Yield	-3.88%	-2.18%	0.17%	-0.14%	0.89%	3.63%	5.54%	7.43%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	-7.2	-9.3	-3.52	-2.18	2.33	7.656	11	14.24
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	844.3	1,037	1,828	2,248	3,714	5,611	7,300	8,721
EBITDA ¹	-661.1	-740.6	-228.1	-120.2	557.2	1,294	1,802	2,239
EBIT ¹	-708.7	-785.1	-282.2	-176.9	501.6	1,290	1,842	2,408
Net income ¹	-852.8	-1,131	-440.2	-278.2	313.7	1,026	1,520	1,983
Net Debt ¹	-1,760	-1,105	-41.37	-222.5	-210.3	-2,937	-4,902	-7,086
Reference price ²	169.58	237.65	191.41	235.31	397.65	297.69	297.69	297.69
Nbr of stocks (in thousands)	119,601	123,028	125,493	128,981	132,114	133,513	-	-
Announcement Date	2/10/22	2/23/23	2/15/24	2/13/25	2/12/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ALNYLAM PHARMACEUTICALS, INC.	38.89x	6.56x	28.45x	-.--%	39.75B
ELI LILLY AND COMPANY	33.49x	12.17x	25.07x	0.6%	1,021B
JOHNSON & JOHNSON	25.33x	5.84x	15.88x	2.25%	571B
ABBVIE INC.	27.6x	6.73x	13.74x	3.04%	398B
ROCHE HOLDING AG	17.1x	4.23x	10.39x	3.14%	319B
ASTRAZENECA PLC	23x	4.78x	13.59x	1.83%	283B
NOVARTIS AG	20.62x	5.33x	12.95x	3.06%	272B
AMGEN INC.	22.4x	6.01x	10.5x	2.93%	186B
NOVO NORDISK A/S	11.92x	4.49x	9.18x	4.21%	185B
GILEAD SCIENCES, INC.	-44.91x	5.43x	30.64x	2.59%	156B
Average	17.55x	6.16x	17.04x	2.36%	342.97B
Weighted average by Cap.	22.78x	7.48x	17.60x	2.09%